“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 10, 2025

Chloride channel activators


Overview
Chloride channel activators are a class of agents that enhance intestinal fluid secretion by directly activating chloride channels on the apical membrane of intestinal epithelial cells. This action increases intestinal motility and facilitates stool passage. They are primarily indicated for the treatment of certain types of chronic constipation and irritable bowel syndrome with constipation (IBS-C).

Mechanism of Action

  • The key drug in this class, lubiprostone, is a bicyclic fatty acid derived from prostaglandin E₁.

  • It selectively activates type-2 chloride channels (ClC-2) in the apical membrane of intestinal epithelial cells.

  • Activation of ClC-2 channels increases chloride ion efflux into the intestinal lumen.

  • Sodium ions and water follow passively, leading to softer stool and increased intestinal transit without significant changes in serum electrolytes.

  • Unlike stimulant laxatives, it works locally in the GI tract with minimal systemic absorption.

Available Agent

  • Lubiprostone (Amitiza) – available in capsule form for oral administration.

Therapeutic Uses

  • Chronic idiopathic constipation (CIC) in adults

  • Irritable bowel syndrome with constipation (IBS-C) in adult women ≥18 years

  • Opioid-induced constipation (OIC) in adults with chronic non-cancer pain

Dosage and Administration

  • Chronic idiopathic constipation: 24 mcg orally twice daily with food and water.

  • IBS-C: 8 mcg orally twice daily with food and water.

  • Opioid-induced constipation: 24 mcg orally twice daily with food and water.

  • Capsules should be swallowed whole; take with food to reduce nausea.

Contraindications

  • Known hypersensitivity to lubiprostone or its components

  • Mechanical gastrointestinal obstruction

Precautions

  • Nausea is common; taking with food can mitigate symptoms

  • Use with caution in severe diarrhea

  • Safety in pregnancy: Category C; use only if potential benefits outweigh risks

  • Not established in pediatric patients for most indications except certain investigational settings

Adverse Effects

  • Common: Nausea, diarrhea, abdominal distension, abdominal pain, flatulence, vomiting, headache

  • Less common: Dyspnea (usually transient and resolves within hours), hypotension (rare)

  • Serious (rare): Severe diarrhea with dehydration

Drug Interactions

  • No major cytochrome P450 interactions due to minimal systemic absorption

  • Additive GI effects with other laxatives or prokinetic agents




on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)